Treatment of Two Children with Hereditary Tyrosinaemia Type I and Long-standing Renal Disease with a 4-hydroxyphenylpyruvate Dioxygenase Inhibitor (NTBC)
Overview
Affiliations
van Ginkel W, Rodenburg I, Harding C, Hollak C, Heiner-Fokkema M, van Spronsen F Paediatr Drugs. 2019; 21(6):413-426.
PMID: 31667718 PMC: 6885500. DOI: 10.1007/s40272-019-00364-4.
Renal tubular function in children with tyrosinaemia type I treated with nitisinone.
Santra S, Preece M, Hulton S, McKiernan P J Inherit Metab Dis. 2008; 31(3):399-402.
PMID: 18509744 DOI: 10.1007/s10545-008-0817-x.
Debray D, Yousef N, Durand P Paediatr Drugs. 2006; 8(1):1-13.
PMID: 16494508 DOI: 10.2165/00148581-200608010-00001.
Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.
Grompe M, Overturf K, Finegold M J Inherit Metab Dis. 1998; 21(5):518-31.
PMID: 9728332 DOI: 10.1023/a:1005462804271.
Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
Holme E, Lindstedt S J Inherit Metab Dis. 1998; 21(5):507-17.
PMID: 9728331 DOI: 10.1023/a:1005410820201.